Science Corporation

1.1 Identity and current stage

Science presents itself as a neural-engineering platform rather than a single-product startup, but the current operating story is much more specific: PRIMA is the asset that has moved the company from research posture into an early commercial phase. The company says it was founded in 2021, and the assigned independent reporting places the headquarters in Alameda, California, with Paris continuity around the PRIMA program. That combination matters because the business is now bifurcated by geography: Europe has a CE-marked product, while the United States still sits in a pre-commercial regulatory path. In practical diligence terms, Science is best framed as an early-commercial retinal-BCI company in Europe and a still-regulatory-stage device company in the U.S., not yet a scaled medtech revenue story.[CO001, CO002, CO003, CO004, CO010]

1.2 Leadership, capital, and governance visibility

Leadership visibility is high at the founder level and much thinner beneath it. Max Hodak remains the primary public face across acquisition, financing, and launch milestones, which is useful for narrative coherence but also signals key-person concentration. The 2026 financing materials show some bench expansion, especially around Darius Shahida’s strategy role, while independent coverage adds Alan Mardinly and Murat Günel to the visible operating roster. Capital access is a real strategic advantage: a $230 million Series C and roughly $490 million cumulative funding give Science more time and infrastructure than most neurotech peers. What the public record still does not give is governance depth—board composition, investor rights, and preference terms remain outside the accessible evidence set.[CO005, CO006, CO007, CO008, CO009, CO016]

1.3 Clinical and regulatory proof points

The strongest foundation under the current story is that Science is not selling an unvalidated concept. The PRIMA launch materials consistently anchor on a clinical package that spans 38 patients, 17 sites, and five countries, alongside outcome claims around letter-score improvement and restored reading ability. That is materially stronger than a typical pre-pivotal BCI narrative. Just as important, the company’s ophthalmic position is not fully homegrown: acquiring PRIMA from Pixium in 2024 supplied the asset that now carries both the clinical evidence and the CE-mark launch. For later chapters, this means PRIMA should be treated as the company’s core proof-of-execution asset, while the rest of the platform remains earlier and less commercially evidenced.[CO010, CO011, CO012]

1.4 Commercial conversion and open metrics

The adverse read is not that Science lacks technical proof; it is that the market still lacks the operating metrics needed to convert a technical breakthrough into an investable business case. Independent reporting explicitly flags the next bottleneck: reimbursement by country, beginning with Germany, rather than the CE mark alone. U.S. commercialization is even less mature because regulatory process remains incomplete despite special designations. At the same time, the most important judgment metrics—valuation support, headcount quality, customer count, revenue, pricing, and board control—remain partially disclosed at best. That combination supports a view of Science as heavily financed and strategically differentiated, but still early in proving commercial repeatability.[CO004, CO013, CO014, CO015, CO016]

1.5 Exhibits

2.1 Market boundary and status-quo substitute

The retained sources define PRIMA's market around a specific late-stage blindness workflow rather than the entire ophthalmology market. PRIMA is described as a subretinal photovoltaic implant plus specialized glasses for adults with geographic atrophy caused by dry age-related macular degeneration, where lost central vision limits reading, facial recognition, and other detail-dependent tasks. That boundary matters because the same sources also frame the status quo differently for earlier and later disease stages: approved drugs can slow lesion growth, but the cited retained evidence says they do not restore vision that has already been lost. Science's first commercial product therefore fits best as a late-stage rescue or restoration modality, not as a general AMD therapy or a replacement for earlier disease management.[CM001, CM002, CM003, CM004, CM011, CM015]

2.2 Evidence-constrained sizing and adjacency

Public evidence supports only an evidence-constrained sizing model. The broad top-down anchor is disease burden: multiple retained sources cite more than five million people globally with AMD-associated geographic atrophy. The next layers narrow quickly because public disclosures do not quantify how many of those patients have the severe central-vision loss, clinical eligibility, and reimbursed access needed for PRIMA today. Instead, the strongest bottom-up evidence is operational: a 38-patient, 17-site, five-country evidence base underlies the CE mark, commercial availability spans 30 European countries, and Germany is the first expected paying market. Science is also extending PRIMA into Stargardt disease and retinitis pigmentosa, which widens strategic adjacency, but those sources still stop short of a source-backed SAM/SOM for the near-term launch.[CM002, CM003, CM005, CM007, CM009, CM010, CM012, CM014]

2.3 Buyer, user, and payer path

The user is clearer than the buyer. Sources consistently identify the patient as a severely sight-impaired adult with geographic atrophy from dry AMD, while the workflow runs through specialist ophthalmology centers that can implant, activate, and follow the device. The payer path is still emerging rather than proven: company and independent coverage say reimbursement applications and site activations are underway across Europe, with Germany expected to host the first commercial implant. That means the commercial sale depends less on theoretical prevalence than on whether retina centers, local reimbursement authorities, and surgeons convert the CE mark into funded procedures. Public materials retained for this chapter do not disclose ASP, reimbursement code, or budget-owner detail, so those economics remain a diligence gap rather than an authored assumption.[CM003, CM005, CM006, CM007, CM013, CM014]

2.4 Adoption drivers and constraints

Science has several real adoption drivers: a differentiated restorative claim, peer-reviewed and widely re-reported trial outcomes, CE-marked access across a broad European footprint, and substantial capitalization earmarked for commercialization, manufacturing, and operations. The same evidence also surfaces the key constraints. Europe is open legally but not yet proven economically because reimbursement remains country-specific and the first commercial implant is only just beginning in Germany. The U.S. path remains investigational despite Breakthrough Device and Humanitarian Use Device designations. And the broader disease burden should not be mistaken for immediate market capture: current public evidence supports a clinically narrow late-stage segment, with pricing, conversion, and center-capacity assumptions still undisclosed.[CM006, CM007, CM008, CM010, CM013, CM014, CM015]

2.5 Exhibits

3.1 Landscape and buyer alternatives

The relevant landscape is broader than implantable retinal devices. A buyer can select PRIMA, wait for a visual-cortex implant such as Neuralink's Blindsight, use treatments intended to slow disease progression, pursue experimental gene therapy, or remain with no restorative intervention. Within the assigned evidence, PRIMA is the only option documented as commercially available in Europe for restoring form vision in geographic atrophy; MobiHealthNews reported CE marking across 30 European countries and identified Blindsight as an adjacent cortical approach. Science acquired PRIMA intellectual property and related assets from Pixium Vision in 2024, so Pixium is better treated as the platform predecessor than as a current operating rival. The resulting map is a partial competitive set, not an exhaustive enumeration of retinal-device, pharmaceutical, or low-vision-assistance alternatives.[CP004, CP008, CP009, CP010]

3.2 Capability differentiation and proof burden

PRIMA combines a photovoltaic subretinal implant with camera-equipped glasses that transmit power and image data through near-infrared light. That architecture preserves a distinct competitive proposition: it stimulates remaining retinal cells rather than the visual cortex and is intended to restore lost functional central vision rather than merely slow progression. The evidence base is meaningful but narrow. The reported pivotal study involved 38 patients at 17 sites in five countries, and multiple assigned sources repeated that 80% achieved the stated visual-acuity threshold at 12 months. Serious adverse events were concentrated early and 95% reportedly resolved within two months, but MassDevice noted that the company did not disclose the number of serious adverse events. Consequently, trial differentiation should not be mistaken for a broad head-to-head benchmark.[CP001, CP002, CP003, CP009, CP010, CP011]

3.3 Commercialization, pricing, and buying friction

Science has moved beyond a premarket-only posture in Europe: its patient page says PRIMA is CE marked in the European Union and registered for supply in the United Kingdom, while independent reporting says the first commercial implantation was expected in Germany. The company also said that country-specific reimbursement applications and clinical-site activations were underway. Those steps create a distribution lead over alternatives represented only by an FDA designation, but they do not establish adoption economics. The assigned evidence contains no disclosed device price, procedure price, realized reimbursement, contract model, discounting, or comparative lifetime cost. Surgical implantation and dedicated glasses plausibly create training and workflow friction, yet no source quantifies switching cost, removal burden, multi-homing, or provider capacity.[CP004, CP005, CP006, CP007, CP012, CP016]

3.4 Moat durability and displacement risk

PRIMA's near-term moat is a bundle of clinical evidence, regulatory clearance, inherited retinal intellectual property, specialized manufacturing, and site activation rather than a proven price or network-effect advantage. Science's $230 million Series C and approximately $490 million of cumulative capital support commercialization and a broader neural-engineering portfolio, while its roadmap extends to a next-generation implant and glasses and additional retinal diseases. This capital and scope may reinforce execution, but the same breadth can diffuse focus. Displacement risk remains material from cortical implants, improved disease-modifying therapies, gene therapy, and future entrants that offer less invasive treatment or stronger reimbursement. The assigned pool does not support a conclusion about comparative funding, clinical efficacy, pricing, surgeon capacity, channel control, or long-term patient retention across these alternatives.[CP008, CP009, CP010, CP013, CP014, CP015, CP016]

3.5 Exhibits

4.1 Revenue model and launch bridge

Public evidence now supports a real revenue mechanism for Science, but not a quantified one. PRIMA is no longer framed solely as a clinical program: Science and multiple trade publications say the device has CE marking, is commercially available across 30 European countries, and is preparing for its first German implant. That moves the company from pure R&D financing into launch execution. The monetization path is still high-touch and sequential rather than software-like: site activation, patient identification, implantation, reimbursement approval, then recognized device/procedure revenue. The missing commercial detail is what keeps the model from being underwritten. The same launch disclosures say reimbursement applications are underway, but none of the retained sources publish ASP, payer rates, discounts, contract terms, or realized implant revenue. Science also continues to describe Biohybrid, Vessel, MEMS Foundry, and the BCI Ecosystem as investment areas, not as separately disclosed revenue contributors, so PRIMA appears to be the only evidenced near-term revenue engine.[CI005, CI006, CI011, CI012, CI013, CI014, CI015]

4.2 Public traction exists, but unit economics do not

The strongest public traction evidence is clinical, not financial. Science’s NEJM summary and launch materials point to a 38-patient, 17-site, five-country study in which 84% of patients reported reading letters, numbers, and words and 80% achieved at least 0.2 logMAR improvement at 12 months. A later 36-month update reported a 29-letter mean improvement among efficacy-evaluable patients. Those outcomes matter commercially because they give Science a differentiated efficacy story for physicians, patients, and payers. But they do not answer the financial questions that an investor would need to price execution: public sources do not disclose realized revenue, implant volumes, gross margin, CAC, payback, cash burn, or service-delivery cost. Even the reimbursement pathway is described only at the process level. The result is a chapter where adoption potential is visible, but the actual conversion of that potential into recurring gross profit remains unobserved.[CI008, CI009, CI010, CI011, CI012]

4.3 Capital adequacy improved, but financing dependency remains

The refresh meaningfully changes Science’s financing position. In March 2026 the company closed a $230 million Series C, bringing total capital raised to about $490 million, and Inside BCI reported an approximate $1.25 billion post-money valuation. Management says the round funds PRIMA commercialization while also expanding research, manufacturing, and operational infrastructure, which implies that this capital is meant to carry both launch and continued platform build-out. That lowers immediate liquidity pressure versus the prior report, but it does not remove financing dependency because there is still no public cash balance, burn, runway, or debt disclosure. Management’s own language is also forward-looking: the goal is to become the first BCI company to scale and achieve profitability, not to demonstrate that profitability has already been reached. Practically, that means the next financing inflection is still likely to depend on evidence that Europe can turn CE marking into reimbursed procedures while the U.S. path remains pending.[CI001, CI002, CI003, CI004, CI007, CI012, CI015]

4.4 Financial verdict and diligence blockers

Science’s financial story is investable only as a milestone transition, not as a fully underwritten operating model. The company now has both a large 2026 funding round and a launched European product, which is a better setup than a pure pre-commercial clinical asset. But nearly every underwriting input that would turn that setup into conviction is still missing from public evidence: no disclosed revenue line, no price realization, no contribution margin, no installation pace, no channel or reimbursement economics, and no current cash-runway statement. The 36-month safety disclosure is directionally reassuring, yet it also confirms that clinical complications and regulatory timing still matter to revenue conversion. The judgment for this chapter is therefore cautious: Science may have enough capital to push PRIMA through early commercialization, but diligence should treat margin path, launch efficiency, and next-round timing as open items until the company discloses actual implant and reimbursement performance.[CI004, CI007, CI010, CI011, CI012, CI015]

4.5 Exhibits

5.1 Delivered system and user workflow

PRIMA is best understood as a treatment workflow for severely sight-impaired adults with geographic atrophy from dry AMD, not as a chip alone. The company and multiple independent write-ups describe a subretinal photovoltaic implant paired with specialized glasses and external compute that projects near-infrared light onto the implant so patients can recover central form vision for tasks such as reading letters, numbers, and words. That matters for diligence because the customer-facing deliverable includes hardware, surgical implantation, image processing, optical wearables, and post-implant support, so technical risk spans the whole stack rather than only the implant itself.[CE001, CE002, CE003, CE005, CE011]

5.2 Clinical maturity, regulatory status, and deployment path

The evidence base is unusually concrete for an implantable neurotechnology company. The pivotal PRIMA program enrolled 38 patients across 17 sites in five countries, with 12-month data showing central-vision restoration for a majority of participants and 36-month follow-up indicating durability among the evaluable cohort. Commercial maturity has also advanced: PRIMA is CE marked in the EU, registered for UK supply, and being launched first through Germany and other European sites before any US commercialization. The main caveat is that the latest durability and launch claims still come primarily from company-issued updates rather than broad post-market evidence.[CE001, CE004, CE005, CE006, CE007, CE008, CE009]

5.3 Differentiation and platform breadth

PRIMA's differentiation is not just that it stimulates the retina; it appears to be the first commercially cleared retinal implant specifically positioned to restore central vision in AMD- related geographic atrophy, a narrower and more defensible claim than generic "first BCI" marketing. Science is also trying to differentiate beyond a single-device company: its March 2026 financing update tied PRIMA commercialization to a broader pipeline that includes other retinal indications, biohybrid interfaces, perfusion technology, and an in-house MEMS foundry and tooling ecosystem. That platform story could matter if manufacturing and iteration speed become a moat, but public evidence today is still strongest for PRIMA itself rather than the adjacent programs.[CE010, CE012, CE013]

5.4 Controls, dependencies, and diligence gaps

Product risk now shifts from proving that PRIMA can work at all to proving that Science can scale it safely and economically. The 36-month update is directionally reassuring because no new safety signal emerged after year one, but surgery-related events were concentrated early and commercialization still depends on country-by-country reimbursement, site activation, and sustained manufacturing quality. Public materials in this source set say little about software validation, cybersecurity, data handling, complaint/CAPA processes, or implant-manufacturing yield, so the diligence burden has moved from clinical plausibility toward operating controls.[CE007, CE009, CE010, CE011]

6.1 Customer surface is still narrow, clinical, and GA-first

Science's current customer surface is narrow and medically specific: PRIMA is aimed first at people blinded by geographic atrophy from age-related macular degeneration, with the public commercial path centered on Europe and especially Germany. Public materials also show a second buyer layer of retina clinicians and hospital sites that evaluate, implant, and seek reimbursement for the system, while retinitis pigmentosa and Stargardt disease remain expansion cohorts rather than today's disclosed paying base. That means the present customer story is still a blend of trial users, activated clinical sites, and pre-commercial demand capture, not a disclosed installed base of recurring accounts.[CU001, CU005, CU006, CU010, CU014]

6.2 Adoption proof is compelling clinically, but commercialization metrics are still sparse

The strongest adoption proof is clinical rather than revenue-based. The 12-month PRIMA dataset covered 38 patients across 17 sites in five countries, with 84% reporting the ability to read letters, numbers, and words and 80% achieving significant prosthetic acuity improvement. By October 2026, 36-month follow-up still showed no new safety signal between months 12 and 36, but only 27 patients were evaluable for safety and 18 for efficacy, so durability evidence remains encouraging yet denominator-limited. Commercially, CE mark approval across 30 European countries and active reimbursement and site activation work indicate launch readiness, but public sources still stop short of disclosing implant counts, revenue by center, or active paid-account totals.[CU002, CU003, CU004, CU011, CU012]

6.3 Named proof exists at the clinician/site layer; retention and concentration are still opaque

Named proof is strongest at the clinician and site layer: Frank Holz at University Hospital of Bonn, Mahi Muqit at Moorfields, and Matthew Simunovic's planned Sydney trials all show specialist adoption surfaces that matter for a surgical retinal product. Science also launched a patient registry intended to identify candidates and track functional measures such as reading, face recognition, and mobility, which is useful evidence of funnel-building. But the assigned public evidence does not disclose churn, renewal, contract length, average selling price, or top-center concentration, so the real durability question is not whether PRIMA can help blinded patients - that proof is compelling - but how quickly activated centers turn into reimbursed, repeat implant volume.[CU007, CU008, CU009, CU013]

6.4 Exhibits

7.1 Regulatory clearance has arrived faster than reimbursement or U.S. approval

PRIMA's CE mark is a meaningful de-risking event because it turns Science from a purely clinical-stage retinal-implant developer into a company with an EU-cleared commercial product, but the available evidence also shows that clearance is only the first gate. Science says DEKRA authorized commercial availability across 30 European countries, yet it simultaneously says reimbursement applications and site activations are still country-specific and that Germany is merely the first expected implant market. Independent coverage makes the same point more starkly: Europe can still fail to convert regulatory clearance into paid procedures if German reimbursement, hospital onboarding, or real-world implant cadence disappoints. On the U.S. side, Science remains in a pre-commercial state; Breakthrough Device and Humanitarian Use Device designations improve engagement with FDA, but they do not authorize launch and still leave the company exposed to timing risk on an eventual Humanitarian Device Exemption decision.[CR001, CR002, CR003, CR004, CR012, CR013]

7.2 Clinical proof is strong, but the operating envelope is still narrow

The clinical case for PRIMA is far better than for most implantable-neurotech launches, yet the operational risk has not disappeared. Science's January summary of the pivotal dataset showed visually meaningful gains across a 38-patient, 17-site European trial, and the October 2026 update extended that story to 36 months without a newly reported safety signal. That is good evidence that the product can work, but it is not the same thing as broad post-market reliability. The 36-month dataset only had 27 patients evaluable for safety and 18 for efficacy, and the adverse-event profile is still fundamentally a surgery-dependent one. Investors therefore need to treat early Europe rollout as a monitored scale-up: every first-wave commercial implant, reimbursement approval, and site activation matters because there is not yet a large installed base to absorb execution noise.[CR005, CR006, CR007, CR008]

7.3 The balance sheet lowers immediate solvency risk but raises execution pressure

Science is not facing a near-term capital drought by startup standards: management says it raised approximately $490 million since 2021, including an oversubscribed $230 million Series C in March 2026, and said the proceeds are intended to commercialize PRIMA while expanding manufacturing and the broader pipeline. That reduces acute fundraising risk for the next launch steps, but it does not remove model risk. Hodak told TechCrunch that the vision business is supposed to finance the company's longer-term biohybrid work, which means PRIMA is not just a product milestone but the economic bridge for the rest of Science's thesis. If reimbursement arrives slowly, manufacturing ramps unevenly, or U.S. approval slips, the company could still face a mismatch between the capital already raised and the revenue proof needed to justify it.[CR009, CR010, CR011]

7.4 The thesis breaks on reimbursement slippage, U.S. delay, or new post-market safety noise

The highest-value diligence now is not another generic technology review; it is a short list of concrete checkpoints. First, confirm whether Germany converts CE-mark clearance into reimbursed procedures at a pace that supports broader EU rollout rather than a symbolic launch. Second, obtain primary evidence on the U.S. regulatory path, because public reporting still describes the HDE/HUD route in directional rather than filed-and-timed terms. Third, test whether the favorable 36-month safety update survives real-world use once commercial implants begin. Finally, pressure-test the company's operating plan by asking how much manufacturing throughput, site capacity, and reimbursement visibility PRIMA must achieve before management can credibly claim that the product is financing the rest of the platform. Missing any of those checkpoints would move the current risk stack from manageable to thesis-breaking.[CR002, CR004, CR006, CR007, CR008, CR011, CR012, CR013]

7.5 Exhibits

8.1 Recommendation and price discipline

Science now has evidence of both product efficacy and initial regulatory commercialization: PRIMA produced peer-reviewed functional-vision gains in a 38-patient, 17-site trial, and the device has since received a CE mark for commercial availability in Europe. That materially improves product and regulatory confidence. The underwriting problem is price, not whether the technology is real. Public valuation support still appears to be a roughly $1.5 billion March 2026 mark circulated by secondary databases and cited by Inside BCI as Bloomberg-reported, while public sources still do not disclose revenue, profitability, or reimbursement economics. At that information level, the investable call is track rather than buy, and entry discipline should assume commercialization proof still has to be earned in market.[CV003, CV004, CV006, CV007, CV008, CV014]

8.2 Why the thesis is promising but not yet investable at price

The positive case is straightforward: Science raised another $230 million in March 2026, bringing total disclosed capital to about $490 million, and management has aimed that capital at PRIMA commercialization plus broader manufacturing and pipeline build-out. Clinical efficacy is unusually concrete for an implantable neurotechnology company, and CE marking gives the company a real launch path instead of a purely precommercial story. The anti-thesis is equally clear. The company is still pre-disclosure on the operating metrics that matter most to valuation support, including revenue, profitability, and cap-table economics. Even its strongest independent valuation references are secondary-source marks, not a company-disclosed benchmark tied to commercial KPIs. That makes the company attractive strategically, but hard to price aggressively today.[CV001, CV002, CV003, CV008, CV011, CV013]

8.3 Scenario ranges and downside triggers

The bull case requires fast conversion of regulatory proof into reimbursed use: Germany must move from expected first commercial implant to repeatable funded procedures, and the U.S. pathway needs to stay on a credible HDE or other approval timetable. In that outcome, the last reported valuation could be sustained or exceeded because Science would look less like a long-dated platform bet and more like the first neurotechnology company with credible product revenue. The base case is slower. CE mark, reimbursement applications, and site activations are real progress, but they do not yet prove adoption or unit economics, so a flat-to-slightly-down outcome versus the last round remains plausible. The bear case is straightforward: narrow reimbursement, delayed uptake, or U.S. slippage would expose how little public revenue evidence supports the current price.[CV004, CV005, CV009, CV010, CV014, CV015]

8.4 Final diligence asks and thesis-break triggers

The next diligence cycle should focus on the handful of facts that can actually move the recommendation. First, obtain German reimbursement terms, target ASP, and early implant cadence; a CE mark without funded procedures is not the same as scalable commercialization. Second, request post-launch operating disclosure: implants completed, booked sites, training throughput, manufacturing yield, and gross margin expectations. Third, inspect the cap table and preference stack, including any participation rights or conversion mechanics that could subordinate new money even if headline valuation appears unchanged. A thesis break would be evidence that Europe remains effectively private-pay or highly limited-access, that the U.S. pathway slips materially, or that the next financing resets below the last reported mark before launch KPIs are visible.[CV005, CV008, CV009, CV010, CV012, CV015]